EP1007526A1 - Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands - Google Patents

Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands

Info

Publication number
EP1007526A1
EP1007526A1 EP98943352A EP98943352A EP1007526A1 EP 1007526 A1 EP1007526 A1 EP 1007526A1 EP 98943352 A EP98943352 A EP 98943352A EP 98943352 A EP98943352 A EP 98943352A EP 1007526 A1 EP1007526 A1 EP 1007526A1
Authority
EP
European Patent Office
Prior art keywords
oxo
naphthyridine
carboxamide
tetrahydro
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98943352A
Other languages
German (de)
English (en)
French (fr)
Inventor
Pamela Albaugh
Robert W. Desimone
Gang Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurogen Corp
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of EP1007526A1 publication Critical patent/EP1007526A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP98943352A 1997-08-25 1998-08-24 Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands Withdrawn EP1007526A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US918180 1992-07-23
US91818097A 1997-08-25 1997-08-25
PCT/US1998/017513 WO1999010347A1 (en) 1997-08-25 1998-08-24 Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands

Publications (1)

Publication Number Publication Date
EP1007526A1 true EP1007526A1 (en) 2000-06-14

Family

ID=25439933

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98943352A Withdrawn EP1007526A1 (en) 1997-08-25 1998-08-24 Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands

Country Status (24)

Country Link
EP (1) EP1007526A1 (zh)
JP (1) JP2001514181A (zh)
KR (1) KR20010023313A (zh)
CN (1) CN1268136A (zh)
AP (1) AP2000001742A0 (zh)
AU (1) AU753800B2 (zh)
BG (1) BG104192A (zh)
BR (1) BR9811362A (zh)
CA (1) CA2301599C (zh)
EG (1) EG21717A (zh)
HU (1) HUP0003258A3 (zh)
IL (1) IL134291A0 (zh)
IS (1) IS5382A (zh)
LV (1) LV12539B (zh)
NO (1) NO20000822L (zh)
NZ (1) NZ502548A (zh)
OA (1) OA11293A (zh)
PE (1) PE130999A1 (zh)
PL (1) PL338783A1 (zh)
SI (1) SI20270A (zh)
SK (1) SK2162000A3 (zh)
TW (1) TW574221B (zh)
WO (1) WO1999010347A1 (zh)
YU (1) YU10500A (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413956B1 (en) * 1999-05-06 2002-07-02 Neurogen Corporation Substituted 4-oxo-quinoline-3-carboxamides
WO2000071528A1 (en) * 1999-05-25 2000-11-30 Neurogen Corporation 4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
IL155089A0 (en) 2000-10-12 2003-10-31 Merck & Co Inc Aza and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
DE60128936T2 (de) 2000-10-12 2008-04-10 Merck & Co, Inc. Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
US6841558B2 (en) 2000-10-12 2005-01-11 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as HIV intergrase inhibitors
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
CN1494422A (zh) * 2001-03-01 2004-05-05 �Ʒ� Gabaa反相激动剂与烟碱受体不完全激动剂、雌激素、选择性雌激素调节剂、或维生素e联合用于认知障碍的用途
AR036256A1 (es) 2001-08-17 2004-08-25 Merck & Co Inc Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento
AU2003216049B2 (en) 2002-01-17 2008-07-17 Merck Sharp & Dohme Corp. Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
US7323460B2 (en) 2002-03-15 2008-01-29 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as HIV integrase inhibitors
WO2004106336A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Process for the preparation and purification of 1,5-naphthyridine-3-carboxyamides
WO2004106334A2 (en) * 2003-05-28 2004-12-09 Pfizer Products Inc. Process for the preparation of 1,5-naphthyridine-3-carboxy amides by direct ester amidation
CA2666219C (en) * 2006-10-16 2017-02-07 Bionomics Limited Novel anxiolytic compounds
CA2670116C (en) * 2006-11-22 2015-03-10 Seaside Therapeutics, Llc Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR204162A1 (es) * 1972-05-08 1975-11-28 Yamanouchi Pharma Co Ltd Proceso para la preparacion de derivados de ampicilina
GB1433774A (en) * 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
US4374138A (en) * 1981-11-13 1983-02-15 Warner-Lambert Company Antibacterial amide compounds, compositions, and methods of use
DD279887A1 (de) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun Verfahren zur herstellung von d-alpha-(4(1h)-1,5-naphthyridon-3-carboxamido)-benzylpenicillin und anderen beta-lactamantibiotika
DD279875A1 (de) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun Verfahren zur herstellung von aktivierten carbonsaeureestern
DD295360A5 (de) * 1987-07-03 1991-10-31 Akad Wissenschaften Verfahren zur Herstellung von aktivierten Carbonsäureestern
JPS6461461A (en) * 1987-09-01 1989-03-08 Otsuka Pharma Co Ltd Benzohetero ring derivative

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9910347A1 *

Also Published As

Publication number Publication date
YU10500A (sh) 2002-10-18
NO20000822D0 (no) 2000-02-18
JP2001514181A (ja) 2001-09-11
NO20000822L (no) 2000-04-13
AP2000001742A0 (en) 2000-02-24
NZ502548A (en) 2002-06-28
HUP0003258A3 (en) 2001-05-28
HUP0003258A2 (en) 2001-03-28
AU753800B2 (en) 2002-10-31
AU9117398A (en) 1999-03-16
IL134291A0 (en) 2001-04-30
SI20270A (sl) 2000-12-31
BR9811362A (pt) 2000-08-22
LV12539B (en) 2001-01-20
PL338783A1 (en) 2000-11-20
IS5382A (is) 2000-02-22
SK2162000A3 (en) 2001-03-12
OA11293A (en) 2002-11-19
WO1999010347A1 (en) 1999-03-04
CA2301599C (en) 2003-03-25
LV12539A (en) 2000-10-20
CN1268136A (zh) 2000-09-27
TW574221B (en) 2004-02-01
BG104192A (en) 2001-05-31
CA2301599A1 (en) 1999-03-04
PE130999A1 (es) 1999-12-16
EG21717A (en) 2002-02-27
KR20010023313A (ko) 2001-03-26

Similar Documents

Publication Publication Date Title
US6399604B1 (en) Substituted 4-OXO-napthyridine-3-carboxamides; GABA brain receptor ligands
US6103903A (en) 4-(4-piperidylmethyhlamino) substituted heteroaryl fused pyridines: GABA brain receptor ligands
US6423711B1 (en) Heterocyclic amino substituted heteroaryl fused pyridines; GABA brain receptor ligands
AU753800B2 (en) Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
US6156898A (en) Substituted 1,4-dihydro-4-oxonicotinic carboxamides; GABA brain receptor ligands
US5908932A (en) Certain pyrroloquinolinones; a new class of GABA brain receptor
US6177569B1 (en) Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands
US6414147B1 (en) 2-amino-9-alkylpurines: GABA brain receptor ligands
US6194427B1 (en) Substituted cycloalkyl-4-Oxonicotinic carboxamides; gaba brain receptor ligands
WO1994005665A1 (en) Certain aryl and cycloalkyl fused imidazopyrazinols; a new class of gaba brain receptor ligands
EP1107966B1 (en) Oxo-pyridoimidazole-carboxamides: gaba brain receptor ligands
MXPA00001598A (en) Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
MXPA01001991A (en) Oxo-pyridoimidazole-carboxamides:gaba brain receptor ligands
MXPA00008364A (en) Substituted cycloalkyl-4-oxonicotinic carboxamides;gaba brain receptor ligands
NZ241986A (en) Imidazo(1,5-a)quinoxaline-1,3,(2h,5h)-dione derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000324

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000324;LT PAYMENT 20000324;LV PAYMENT 20000324;MK PAYMENT 20000324;RO PAYMENT 20000324;SI PAYMENT 20000324

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20060525